Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by HASHEM EL-SERAG and JENNIFER KRAMER.
HASHEM EL-SERAG
Connection Strength
17.223
JENNIFER KRAMER
  1. The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus. Clin Gastroenterol Hepatol. 2023 04; 21(4):1111-1113.e3.
    View in: PubMed
    Score: 0.829
  2. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Aliment Pharmacol Ther. 2019 06; 49(11):1442-1447.
    View in: PubMed
    Score: 0.676
  3. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016 07; 64(1):130-7.
    View in: PubMed
    Score: 0.551
  4. Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus. Gut. 2016 08; 65(8):1252-60.
    View in: PubMed
    Score: 0.527
  5. Use and yield of endoscopy in patients with uncomplicated gastroesophageal reflux disorder. JAMA Intern Med. 2014 Mar; 174(3):462-5.
    View in: PubMed
    Score: 0.475
  6. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut. 2014 Feb; 63(2):220-9.
    View in: PubMed
    Score: 0.442
  7. Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men. Clin Gastroenterol Hepatol. 2013 Apr; 11(4):373-381.e1.
    View in: PubMed
    Score: 0.436
  8. Practice patterns of surveillance endoscopy in a Veterans Affairs database of 29,504 patients with Barrett's esophagus. Gastrointest Endosc. 2012 Oct; 76(4):743-55.
    View in: PubMed
    Score: 0.431
  9. Patient-centered, comparative effectiveness of esophageal cancer screening: protocol for a comparative effectiveness research study to inform guidelines for evidence-based approach to screening and surveillance endoscopy. BMC Health Serv Res. 2012 Aug 28; 12:288.
    View in: PubMed
    Score: 0.428
  10. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol. 2012 Feb; 56(2):320-5.
    View in: PubMed
    Score: 0.396
  11. Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. Hepatology. 2011 Jan; 53(1):42-52.
    View in: PubMed
    Score: 0.380
  12. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol. 2011 Mar; 106(3):483-91.
    View in: PubMed
    Score: 0.378
  13. Hepatitis C infection: dying with or from the infection? J Hepatol. 2008 Feb; 48(2):183-4.
    View in: PubMed
    Score: 0.308
  14. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther. 2008 Feb 01; 27(3):274-82.
    View in: PubMed
    Score: 0.307
  15. Effect of human immunodeficiency virus and antiretrovirals on outcomes of hepatitis C: a systematic review from an epidemiologic perspective. Clin Gastroenterol Hepatol. 2007 Nov; 5(11):1321-1328.e7.
    View in: PubMed
    Score: 0.306
  16. Obesity increases oesophageal acid exposure. Gut. 2007 Jun; 56(6):749-55.
    View in: PubMed
    Score: 0.287
  17. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol. 2005 Oct; 100(10):2151-6.
    View in: PubMed
    Score: 0.265
  18. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol. 2005 Mar; 42(3):309-14.
    View in: PubMed
    Score: 0.255
  19. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol. 2005 Jan; 100(1):56-63.
    View in: PubMed
    Score: 0.252
  20. Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3296-3304.e3.
    View in: PubMed
    Score: 0.224
  21. Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection. Am J Gastroenterol. 2022 11 01; 117(11):1834-1844.
    View in: PubMed
    Score: 0.214
  22. Reply. Hepatology. 2022 Aug; 76(2):E50.
    View in: PubMed
    Score: 0.209
  23. Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population. Am J Drug Alcohol Abuse. 2022 07 04; 48(4):445-453.
    View in: PubMed
    Score: 0.205
  24. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology. 2022 06; 75(6):1420-1428.
    View in: PubMed
    Score: 0.204
  25. Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection. Infect Dis Ther. 2020 Jun; 9(2):355-365.
    View in: PubMed
    Score: 0.182
  26. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology. 2020 03; 71(3):808-819.
    View in: PubMed
    Score: 0.180
  27. Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral Res. 2020 02; 174:104698.
    View in: PubMed
    Score: 0.178
  28. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology. 2020 01; 71(1):44-55.
    View in: PubMed
    Score: 0.174
  29. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018 12; 155(6):1828-1837.e2.
    View in: PubMed
    Score: 0.162
  30. Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system. J Viral Hepat. 2018 11; 25(11):1270-1279.
    View in: PubMed
    Score: 0.161
  31. Hepatitis C virus-related complications are increasing in women veterans: A national cohort study. J Viral Hepat. 2017 11; 24(11):955-965.
    View in: PubMed
    Score: 0.151
  32. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017 10; 153(4):996-1005.e1.
    View in: PubMed
    Score: 0.149
  33. Trends in 30-Day and 1-Year Mortality Among Patients Hospitalized With Cirrhosis From 2004 to 2013. Am J Gastroenterol. 2017 Aug; 112(8):1287-1297.
    View in: PubMed
    Score: 0.149
  34. Tuberculosis Screening and Reactivation Among a National Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Antagonists. Inflamm Bowel Dis. 2017 02; 23(2):254-260.
    View in: PubMed
    Score: 0.146
  35. Prevalence of Celiac Disease Among Unsuspected Patients Presenting to Open Access Endoscopy. Clin Gastroenterol Hepatol. 2017 01; 15(1):137-139.
    View in: PubMed
    Score: 0.141
  36. Early outpatient follow-up and 30-day outcomes in patients hospitalized with cirrhosis. Hepatology. 2016 08; 64(2):569-81.
    View in: PubMed
    Score: 0.138
  37. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat. 2016 09; 23(9):687-96.
    View in: PubMed
    Score: 0.137
  38. Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans. Clin Gastroenterol Hepatol. 2016 Feb; 14(2):301-8.e1-2.
    View in: PubMed
    Score: 0.131
  39. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study. Gastroenterology. 2015 Nov; 149(6):1392-8.
    View in: PubMed
    Score: 0.131
  40. Physical activity and the risk of Barrett's esophagus. Dis Esophagus. 2016 Apr; 29(3):248-54.
    View in: PubMed
    Score: 0.127
  41. The incidence of esophageal adenocarcinoma in a national veterans cohort with Barrett's esophagus. Am J Gastroenterol. 2014 Dec; 109(12):1862-8; quiz 1861, 1869.
    View in: PubMed
    Score: 0.124
  42. Esophageal COX-2 expression is increased in Barrett's esophagus, obesity, and smoking. Dig Dis Sci. 2015 Jan; 60(1):65-73.
    View in: PubMed
    Score: 0.123
  43. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014 Sep; 109(9):1427-35.
    View in: PubMed
    Score: 0.122
  44. Risk of upper gastrointestinal cancers in patients with gastroesophageal reflux disease after a negative screening endoscopy. Clin Gastroenterol Hepatol. 2015 Feb; 13(2):280-6.
    View in: PubMed
    Score: 0.122
  45. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014 Jul; 60(1):98-105.
    View in: PubMed
    Score: 0.121
  46. Fat mass by bioelectrical impedance analysis is not associated with increased risk of Barrett esophagus. J Clin Gastroenterol. 2014 Mar; 48(3):218-23.
    View in: PubMed
    Score: 0.119
  47. Personal and family history of cancer and the risk of Barrett's esophagus in men. Dis Esophagus. 2015 Apr; 28(3):283-90.
    View in: PubMed
    Score: 0.119
  48. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology. 2014 May; 146(5):1249-55.e1.
    View in: PubMed
    Score: 0.118
  49. Barrett's esophagus suspected at endoscopy but no specialized intestinal metaplasia on biopsy, what's next? Am J Gastroenterol. 2014 Feb; 109(2):178-82.
    View in: PubMed
    Score: 0.117
  50. Poor sleep quality and obstructive sleep apnea in patients with GERD and Barrett's esophagus. Neurogastroenterol Motil. 2014 Mar; 26(3):346-52.
    View in: PubMed
    Score: 0.117
  51. No significant effects of smoking or alcohol consumption on risk of Barrett's esophagus. Dig Dis Sci. 2014 Jan; 59(1):108-16.
    View in: PubMed
    Score: 0.116
  52. Dietary consumption of meat, fat, animal products and advanced glycation end-products and the risk of Barrett's oesophagus. Aliment Pharmacol Ther. 2013 Oct; 38(7):817-24.
    View in: PubMed
    Score: 0.115
  53. Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study. Clin Gastroenterol Hepatol. 2014 Feb; 12(2):229-238.e3.
    View in: PubMed
    Score: 0.114
  54. Hepatocellular carcinoma screening practices in the Department of Veterans Affairs: findings from a national facility survey. Dig Dis Sci. 2013 Nov; 58(11):3117-26.
    View in: PubMed
    Score: 0.114
  55. Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans. Am J Gastroenterol. 2013 Oct; 108(10):1576-83.
    View in: PubMed
    Score: 0.114
  56. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2013 Aug; 58(2):538-45.
    View in: PubMed
    Score: 0.113
  57. Age at onset of GERD symptoms predicts risk of Barrett's esophagus. Am J Gastroenterol. 2013 Jun; 108(6):915-22.
    View in: PubMed
    Score: 0.112
  58. The incidence and prevalence of inflammatory bowel disease among U.S. veterans: a national cohort study. Inflamm Bowel Dis. 2013 Apr; 19(5):1059-64.
    View in: PubMed
    Score: 0.112
  59. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013 May; 57(5):1858-68.
    View in: PubMed
    Score: 0.111
  60. The prevalence of oesophageal eosinophilia and eosinophilic oesophagitis: a prospective study in unselected patients presenting to endoscopy. Aliment Pharmacol Ther. 2013 Apr; 37(8):825-32.
    View in: PubMed
    Score: 0.111
  61. Dietary intake of vegetables, folate, and antioxidants and the risk of Barrett's esophagus. Cancer Causes Control. 2013 May; 24(5):1005-14.
    View in: PubMed
    Score: 0.111
  62. Occupational exposure and the risk of Barrett's esophagus: a case-control study. Dig Dis Sci. 2013 Jul; 58(7):1967-75.
    View in: PubMed
    Score: 0.110
  63. Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol. 2013 Jan; 108(1):65-71.
    View in: PubMed
    Score: 0.109
  64. Automated identification of surveillance colonoscopy in inflammatory bowel disease using natural language processing. Dig Dis Sci. 2013 Apr; 58(4):936-41.
    View in: PubMed
    Score: 0.108
  65. Myelosuppression monitoring after immunomodulator initiation in veterans with inflammatory bowel disease: a national practice audit. Aliment Pharmacol Ther. 2012 Dec; 36(11-12):1049-56.
    View in: PubMed
    Score: 0.108
  66. The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs. Gastroenterology. 2012 Jul; 143(1):70-7.
    View in: PubMed
    Score: 0.104
  67. The association between Barrett's esophagus and Helicobacter pylori infection: a meta-analysis. Helicobacter. 2012 Jun; 17(3):163-75.
    View in: PubMed
    Score: 0.104
  68. Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. Clin Gastroenterol Hepatol. 2012 Apr; 10(4):428-33.
    View in: PubMed
    Score: 0.102
  69. Risk of colorectal cancer among Caucasian and African American veterans with ulcerative colitis. Inflamm Bowel Dis. 2012 Jun; 18(6):1011-7.
    View in: PubMed
    Score: 0.100
  70. Level of a-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011 Nov; 9(11):989-94.
    View in: PubMed
    Score: 0.099
  71. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011 Jul; 60(7):992-7.
    View in: PubMed
    Score: 0.096
  72. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011 Jan 18; 154(2):85-93.
    View in: PubMed
    Score: 0.096
  73. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011 Apr; 140(4):1182-1188.e1.
    View in: PubMed
    Score: 0.095
  74. Surveillance for hepatocellular carcinoma: development and validation of an algorithm to classify tests in administrative and laboratory data. Dig Dis Sci. 2010 Nov; 55(11):3241-51.
    View in: PubMed
    Score: 0.094
  75. Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large Veterans Administration Medical Centre. Aliment Pharmacol Ther. 2008 Nov 01; 28(9):1078-87.
    View in: PubMed
    Score: 0.081
  76. Lagtimes in diagnosis and treatment of colorectal cancer: determinants and association with cancer stage and survival. Aliment Pharmacol Ther. 2008 Nov 01; 28(9):1166-74.
    View in: PubMed
    Score: 0.081
  77. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol. 2007 Oct; 47(4):506-13.
    View in: PubMed
    Score: 0.074
  78. Is there a race-based disparity in the survival of veterans with HIV? J Gen Intern Med. 2006 Jun; 21(6):613-7.
    View in: PubMed
    Score: 0.069
  79. Survival in hepatitis C and HIV co-infection: a cohort study of hospitalized veterans. Clin Gastroenterol Hepatol. 2005 Feb; 3(2):175-83.
    View in: PubMed
    Score: 0.063
  80. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med. 2004 Nov 22; 164(21):2349-54.
    View in: PubMed
    Score: 0.062
  81. GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
    View in: PubMed
    Score: 0.062
  82. Defining and Understanding Diagnostic Delays Among Pancreatic Cancer Patients: A Retrospective Cohort Study. Clin Gastroenterol Hepatol. 2024 Jul 27.
    View in: PubMed
    Score: 0.061
  83. Emergency Presentations Predict Worse Outcomes Among Patients with Pancreatic Cancer. Dig Dis Sci. 2024 Feb; 69(2):603-614.
    View in: PubMed
    Score: 0.059
  84. The Impact of Race on Pancreatic Cancer Treatment and Survival in the Nationwide Veterans Affairs Healthcare System. Pancreas. 2024 Jan 01; 53(1):e27-e33.
    View in: PubMed
    Score: 0.058
  85. Diabetes Status and Pancreatic Cancer Survival in the Nationwide Veterans Affairs Healthcare System. Dig Dis Sci. 2023 09; 68(9):3634-3643.
    View in: PubMed
    Score: 0.057
  86. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol. 2023 03; 78(3):493-500.
    View in: PubMed
    Score: 0.054
  87. Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC). Dig Dis Sci. 2023 03; 68(3):1060-1070.
    View in: PubMed
    Score: 0.053
  88. Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. J Hepatol. 2022 02; 76(2):294-301.
    View in: PubMed
    Score: 0.050
  89. Spatial Characteristics of Colonic Mucosa-Associated Gut Microbiota in Humans. Microb Ecol. 2022 Apr; 83(3):811-821.
    View in: PubMed
    Score: 0.049
  90. Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality. JAMA Netw Open. 2020 11 02; 3(11):e2023780.
    View in: PubMed
    Score: 0.047
  91. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology. 2020 10; 72(4):1242-1252.
    View in: PubMed
    Score: 0.047
  92. The Incidence and Prevalence of Anxiety, Depression, and Post-traumatic Stress Disorder in a National Cohort of US Veterans With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020 08 20; 26(9):1423-1428.
    View in: PubMed
    Score: 0.047
  93. Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. J Hepatol. 2020 12; 73(6):1425-1433.
    View in: PubMed
    Score: 0.046
  94. Dietary quality and the colonic mucosa-associated gut microbiome in humans. Am J Clin Nutr. 2019 09 01; 110(3):701-712.
    View in: PubMed
    Score: 0.043
  95. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents. Dig Dis Sci. 2019 11; 64(11):3328-3336.
    View in: PubMed
    Score: 0.042
  96. Dietary Nutrients Involved in One-Carbon Metabolism and Colonic Mucosa-Associated Gut Microbiome in Individuals with an Endoscopically Normal Colon. Nutrients. 2019 Mar 13; 11(3).
    View in: PubMed
    Score: 0.042
  97. Risk Trajectories for Readmission and Death After Cirrhosis-Related Hospitalization. Dig Dis Sci. 2019 06; 64(6):1470-1477.
    View in: PubMed
    Score: 0.042
  98. Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. J Hepatol. 2019 04; 70(4):639-647.
    View in: PubMed
    Score: 0.041
  99. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists. Dig Dis Sci. 2018 06; 63(6):1551-1557.
    View in: PubMed
    Score: 0.040
  100. Positive Predictive Value of International Classification of Diseases, 10th Revision, Codes for Cirrhosis and Its Related Complications. Clin Gastroenterol Hepatol. 2018 10; 16(10):1677-1678.
    View in: PubMed
    Score: 0.039
  101. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. Aliment Pharmacol Ther. 2017 11; 46(10):992-1000.
    View in: PubMed
    Score: 0.038
  102. Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2018 02; 16(2):252-259.
    View in: PubMed
    Score: 0.038
  103. Accurate Identification of Fatty Liver Disease in Data Warehouse Utilizing Natural Language Processing. Dig Dis Sci. 2017 10; 62(10):2713-2718.
    View in: PubMed
    Score: 0.038
  104. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol. 2017 02; 66(2):355-362.
    View in: PubMed
    Score: 0.036
  105. Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers. Am J Gastroenterol. 2016 12; 111(12):1778-1787.
    View in: PubMed
    Score: 0.036
  106. Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. Clin Infect Dis. 2016 08 01; 63(3):291-9.
    View in: PubMed
    Score: 0.035
  107. Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia. Dig Dis Sci. 2016 06; 61(6):1714-20.
    View in: PubMed
    Score: 0.034
  108. Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2016 Jan; 14(1):124-31.e1.
    View in: PubMed
    Score: 0.033
  109. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2014 Dec; 60(6):1871-8.
    View in: PubMed
    Score: 0.031
  110. Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data. Aliment Pharmacol Ther. 2014 Oct; 40(8):949-54.
    View in: PubMed
    Score: 0.031
  111. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015 Mar; 13(3):594-601.e1.
    View in: PubMed
    Score: 0.031
  112. The quality of care provided to patients with varices in the department of Veterans Affairs. Am J Gastroenterol. 2014 Jul; 109(7):934-40.
    View in: PubMed
    Score: 0.030
  113. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol. 2015 Jan; 110(1):10-4.
    View in: PubMed
    Score: 0.030
  114. Association between facility characteristics and the process of care delivered to patients with hepatitis C virus infection. Dig Dis Sci. 2014 Feb; 59(2):273-81.
    View in: PubMed
    Score: 0.029
  115. Patients' intuitive judgments about surveillance endoscopy in Barrett's esophagus: a review and application to models of decision-making. Dis Esophagus. 2013 Sep-Oct; 26(7):682-9.
    View in: PubMed
    Score: 0.028
  116. Process of care for hepatitis C infection is linked to treatment outcome and virologic response. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1270-1277.e3.
    View in: PubMed
    Score: 0.027
  117. The performance of process measures in hepatitis C. Am J Gastroenterol. 2012 Oct; 107(10):1512-21.
    View in: PubMed
    Score: 0.027
  118. An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):709-17.
    View in: PubMed
    Score: 0.023
  119. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007 May 09; 297(18):2010-7.
    View in: PubMed
    Score: 0.019
  120. The association of body mass index with Barrett's oesophagus. Aliment Pharmacol Ther. 2005 Nov 15; 22(10):1005-10.
    View in: PubMed
    Score: 0.017
  121. Evaluation for liver transplantation: adherence to AASLD referral guidelines in a large Veterans Affairs center. Liver Transpl. 2005 Nov; 11(11):1370-8.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.